Ihor E Kopka

USPTO Granted Patents = 21 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 5.4

ph-index = 10

Forward Citations = 222(Granted Patents)

Location History:

Newark, NJ (US) (1987 - 1990)
Millburn, NJ (US) (1994 - 2000)
Hampton, NJ (US) (2012 - 2014)
Warren, NJ (US) (2003 - 2015)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

Years Active: 1987-2015

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9029377 - Platelet-activating factor receptor antagonists (2015-05-12),

2. 8729104 - Diphenyl substituted alkanes as flap inhibitors (2014-05-20),

3. 8653260 - Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists (2014-02-18),

4. 8501786 - Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists (2013-08-06),

5. 8440672 - Diphenyl substituted alkanes (2013-05-14),

6. 8399480 - Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists (2013-03-19),

7. 8247415 - Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists (2012-08-21),

8. 7405221 - Substituted pyrimidines (2008-07-29),

9. 6645939 - Substituted &bgr;-alanine derivatives as cell adhesion inhibitors (2003-11-11),

10. 6090785 - Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents (2000-07-18),

11. 5932551 - Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative (1999-08-03),

12. 5929094 - Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists (1999-07-27),

13. 5750549 - Cycloalkyl tachykinin receptor antagonists (1998-05-12),

14. 5693809 - Substituted 4-aza-5.alpha.-androstan-ones as 5.alpha.-reductase (1997-12-02),

15. 5672583 - Carboxy-peptidyl derivatives as antidegenerative active agents (1997-09-30),

Title: The Innovative Journey of Inventor Ihor E Kopka

Introduction:

Ihor E Kopka, a prolific inventor based in Millburn, NJ (US), has left an indelible mark in the field of pharmaceuticals with his groundbreaking patents. With a total of 21 patents to his name, Kopka's contributions have significantly advanced the realms of cardiovascular and immune disorder treatments.

Latest Patents:

Kopka's latest patents include Platelet-activating factor receptor antagonists, encompassing cyclohexyl sulfonamide compounds that serve as potent PAF receptor antagonists. These compounds exhibit promising potential in treating atherosclerosis and various PAF-mediated disorders such as inflammatory, cardiovascular, and immune disorders. Additionally, his invention of Diphenyl substituted alkanes as flap inhibitors has unveiled compounds that act as 5-lipoxygenase activating protein inhibitors. These compounds offer therapeutic benefits in combating atherosclerosis, asthma, allergies, inflammation, and providing cytoprotective effects.

Career Highlights:

Throughout his career, Ihor E Kopka has collaborated with esteemed pharmaceutical companies such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His innovative mindset and dedication to advancing pharmaceutical research have propelled him to the forefront of the industry, where his patents continue to make a significant impact on healthcare and treatment advancements.

Collaborations:

Kopka has had the privilege of collaborating with notable coworkers, including Philippe L Durette and William K Hagmann. Together, they have contributed to pioneering research and development projects that have reshaped the landscape of pharmaceutical innovations.

Conclusion:

In conclusion, Ihor E Kopka's inventive spirit and unwavering commitment to progress have solidified his position as a trailblazer in the pharmaceutical industry. His patents stand as a testament to his profound contributions towards addressing critical medical needs and improving the quality of life for individuals worldwide.

This text is generated by artificial intelligence and may not be accurate.